Circulation
Circulation
4 years ago

Canagliflozin: Cui Bono?

Mikhail Kosiborod, Matthew A Cavender
Cardiovascular disease accounts for the majority of excess deaths seen in patients with Type 2 diabetes (T2D).(1) Thus, in order to improve outcomes in this population, clinicians should focus on therapies that decrease the risk of subsequent cardiovascular events. Over the last two years, randomized controlled clinical trials have identified several agents that decrease cardiovascular events in patients with T2D with or at high risk for cardiovascular disease (CVD) - effects likely unrelated to glucose-lowering, the indication for which they were originally developed.(2-5) One of these therapies (empagliflozin), a sodium glucose co-transporter-2 inhibitor (SGLT-2i), was found to reduce the risks of major adverse cardiovascular events (MACE), CV death, hospitalization for heart failure, and progression of nephropathy in patients with CVD.(2) However, it is unknown whether SGLT-2i can also reduce cardiovascular events in the lower risk population of patients with T2D but without established CVD.

Publisher URL: http://doi.org/10.1161/CIRCULATIONAHA.117.032198

DOI: 10.1161/CIRCULATIONAHA.117.032198

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.